Patents by Inventor Antonio J. Grillo-Lopez

Antonio J. Grillo-Lopez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of chimeric anti-CD20 antibody as in vitro or in vivo purging agent in patients receiving BMT or PBSC transplant
    Publication number: 20040213784
    Abstract: The use of a chimeric anti-CD20 antibody, RITUXAN®, as an in vivo or in vitro purging agent, of patients receiving bone marrow or peripheral blood stem cell transplant during treatment of B-cell-related malignancies, e.g., B-cell lymphomas or leukemias, is disclosed. Such purging may enhance engraftment and/or prevent disease relapse in such patients.
    Type: Application
    Filed: May 21, 2004
    Publication date: October 28, 2004
    Applicant: Idec Pharmaceuticals Corporation
    Inventors: Antonio J. Grillo-Lopez, John Leonard
  • Combination therapies for B-cell lynphomas comprising administration of anti-CD20 antibody
    Publication number: 20030206903
    Abstract: New combined therapeutic regimens for treatment of B-cell lymphomas are disclosed which comprise in particular administration of anti-CD20 antibodies to patients having low-, intermediate- or high-grade non-Hodgkins lymphomas.
    Type: Application
    Filed: May 19, 2003
    Publication date: November 6, 2003
    Applicant: IDEC Pharmaceuticals Corporation
    Inventor: Antonio J. Grillo-Lopez
  • Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibody
    Publication number: 20030026804
    Abstract: New combined therapeutic regimens for treatment of B-cell lymphomas are disclosed which comprise in particular administration of anti-CD20 antibodies to patients having low-, intermediate- or high-grade non-Hodgkins lymphomas.
    Type: Application
    Filed: July 17, 2002
    Publication date: February 6, 2003
    Applicant: IDEC Pharmaceuticals Corporation
    Inventor: Antonio J. Grillo-Lopez
  • Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibody
    Patent number: 6455043
    Abstract: New combined therapeutic regimens for treatment of B-cell lymphomas are disclosed which comprise in particular administration of anti-CD20 antibodies to patients having low-, intermediate- or high-grade non-Hodgkins lymphomas.
    Type: Grant
    Filed: August 11, 1999
    Date of Patent: September 24, 2002
    Assignee: IDEC Pharmaceuticals Corporation
    Inventor: Antonio J. Grillo-López
  • Intrathecal administration of rituximab for treatment of central nervous system lymphomas
    Publication number: 20020009444
    Abstract: This invention describes methods of using anti-B cell antibodies, preferably anti-CD20 antibodies, and most preferably Rituximab, to treat B cell lymphomas of the brain, especially primary central nervous system lymphomas (PCNSLs), and to prevent meningeal relapse. The antibodies can be administered intrathecally alone, or in combination with other chemotherapeutics, such as methotrexate, or other anti-B cell antibodies to treat PCNSL in both immunocompromised and non-immunocompromised patients. These antibodies can also be used to diagnose patients with CNS lymphoma, especially in immunocompromised patients.
    Type: Application
    Filed: April 25, 2001
    Publication date: January 24, 2002
    Applicant: IDEC Pharmaceuticals Corporation
    Inventor: Antonio J. Grillo-Lopez